Legal Action Initiated Against Humacyte, Inc. for Securities Fraud
LOS ANGELES, Jan. 13, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz have announced that investors experiencing losses related to Humacyte, Inc. (“Humacyte” or the “Company”) HUMA can become lead plaintiffs in a securities fraud class action lawsuit.
Attention Investors: Act Before January 17, 2025
If you suffered losses in Humacyte, Inc. (HUMA), click here to join the ongoing securities fraud lawsuit before the lead plaintiff deadline of January 17, 2025.
Lawsuit Allegations
The complaint asserts that between May 10, 2024 and October 17, 2024, Humacyte’s management failed to inform investors about critical issues, including: (1) non-compliance of the Company’s Durham, North Carolina facility with manufacturing standards, (2) delays in the FDA’s review of the BLA while Humacyte addressed these shortcomings, (3) significant risk to FDA approval of ATEV for vascular trauma, and (4) that their positive representations of business operations were misleading and lacked a solid foundation.
Getting More Information
To learn more about this lawsuit or to ask questions regarding your rights as an investor, please reach out to us.
The Law Offices of Frank R. Cruz,
Email: info@frankcruzlaw.com
Call: 310-914-5007
Website: www.frankcruzlaw.com
Follow us on Twitter for updates: twitter.com/FRC_LAW.
If you contact us via email, please include your mailing address, phone number, and details about your investment in Humacyte.
To become part of this class action, no immediate action is required on your part; you may choose to hire legal counsel or take no steps and remain part of the class.
This press release might be considered Attorney Advertising in certain jurisdictions according to local laws and ethical standards.
View the original content to download multimedia: here.
SOURCE: The Law Offices of Frank R. Cruz, Los Angeles
Market News and Data brought to you by Benzinga APIs